BioSerene

BioSerene is a clinical-stage biotechnology company dedicated to the discovery and development of next-generation small molecule therapeutics, with a primary focus on oncology. The company utilizes a proprietary synthetic lethality platform to identify and target specific genetic vulnerabilities in cancer cells, particularly within the DNA damage response (DDR) pathway. BioSerene's lead candidate, BSN-01, is a potent and selective USP1 inhibitor currently undergoing Phase 1 clinical trials for the treatment of advanced solid tumors. With a strategic presence in both the United States and China, the company leverages global resources to accelerate its pipeline of precision medicines. BioSerene is backed by prominent life science investors and aims to address significant unmet needs in cancer treatment through innovative science.